Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical Indus is well positioned for a sustained re-rating because its leadership under Richard Francis since 2023 has already demonstrated stronger commercial execution, margin discipline, and a credible shift from a generics-led model toward a branded, innovation-driven portfolio. AUSTEDO remains a key earnings engine, with revenue cited at about $2.26B in 2025 and a path toward roughly $3.4B in 2030E as higher dose intensity and broader XR adoption more than offset the 2027 IRA price pressure, while UZEDY, AJOVY, and the generics and biosimilars base add diversification and cash flow resilience. The outlook is further supported by pipeline assets with meaningful upside, especially duvakitug’s positive Phase 2b data in UC and Crohn’s disease and TEV-408’s promising early celiac and vitiligo results, which could expand Teva’s high-margin innovative revenue mix over time.

Teva Pharmaceutical Indus is under pressure because its earnings base remains highly exposed to volatile generic pricing, and any renewed margin compression would weaken cash generation needed to fund an innovative pipeline. The outlook also depends heavily on execution across key growth drivers—AUSTEDO, olanzapine LAI, and duvakitug—where slower market growth, restrictive labeling, or disappointing Phase 3 results could reduce peak sales and margin expectations. In addition, the company faces meaningful downside from a stalled biosimilar push, possible accelerated generic entry for AUSTEDO from April 2033, and unresolved opioid, price-fixing, and environmental contingencies that could impair de-levering.